Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The IASLC 2022 Targeted Therapies of Lung Cancer Meeting will take place February 23 – 26, 2022, and will feature novel research on emerging combination immunotherapy approaches and targets such as KRAS, G12C, and HER2. Relevant topics of effective therapeutic control of resistance to targeted therapies as well as the state of development of antibody-drug conjugates will be included in the program.   

IASLC TTLC 2022

IASLC 2022 Targeted Therapies of Lung Cancer Meeting
23–26 February 2022 | Santa Monica, CA

IASLC TTLC 2022

IASLC 2022 Targeted Therapies of Lung Cancer Meeting
23–26 February 2022 | Santa Monica, CA
The IASLC 2022 Targeted Therapies of Lung Cancer Meeting will take place February 23 – 26, 2022, and will feature novel research on emerging combination immunotherapy approaches and targets such as KRAS, G12C, and HER2. Relevant topics of effective therapeutic control of resistance to targeted therapies as well as the state of development of antibody-drug conjugates will be included in the program.   
Selecting patients with NSCLC who benefit from immunotherapy or targeted therapies 2:20
Selecting patients with NSCLC who benefit from immunotherapy or targeted therapies
Jay Lee • 18 Feb 2022
Addressing unmet needs in patients with lung cancer 1:49
Addressing unmet needs in patients with lung cancer
Nathan Pennell • 21 Feb 2022
Concurrent checkpoint inhibition with chemoradiotherapy in NSCLC 1:27
Concurrent checkpoint inhibition with chemoradiotherapy in NSCLC
Nathan Pennell • 21 Feb 2022
The role of radiotherapy in mesothelioma and thymic carcinoma 1:29
The role of radiotherapy in mesothelioma and thymic carcinoma
Charles Simone • 28 Feb 2022
Proton therapy in thoracic cancer and mesothelioma 1:27
Proton therapy in thoracic cancer and mesothelioma
Charles Simone • 28 Feb 2022
Lineage plasticity in EFGR-mutant lung cancer 1:53
Lineage plasticity in EFGR-mutant lung cancer
Ryan Gentzler • 17 Feb 2022
Recent approvals in the NSCLC treatment landscape 1:56
Recent approvals in the NSCLC treatment landscape
Ryan Gentzler • 17 Feb 2022
Unanswered questions in treating lung cancer with immunotherapy 2:46
Unanswered questions in treating lung cancer with immunotherapy
Jia Luo • 25 Feb 2022
Assessing immunotherapy in various subtypes of lung cancer 1:48
Assessing immunotherapy in various subtypes of lung cancer
Jia Luo • 25 Feb 2022
What the future holds for antibodies in treating NSCLC 0:57
What the future holds for antibodies in treating NSCLC
Ryan Gentzler • 17 Feb 2022
The current treatment landscape for SCLC 2:53
The current treatment landscape for SCLC
Triparna Sen • 21 Feb 2022
Assessing the impact of atezolizumab in NSCLC 1:21
Assessing the impact of atezolizumab in NSCLC
Liza Villaruz • 18 Feb 2022
Novel immunotherapy and small molecule inhibitor combinations 2:14
Novel immunotherapy and small molecule inhibitor combinations
Liza Villaruz • 18 Feb 2022
The future of anti-PD-1 therapies in the NSCLC treatment landscape 2:19
The future of anti-PD-1 therapies in the NSCLC treatment landscape
Nathan Pennell • 21 Feb 2022
Moving immunotherapy to earlier lines in NSCLC 2:22
Moving immunotherapy to earlier lines in NSCLC
Nathan Pennell • 21 Feb 2022
Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091 2:01
Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091
Jay Lee • 18 Feb 2022
The content of VJOncology is intended for healthcare professionals